The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension

Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and pharmacodynamics of IBI3016 in patients with mild to moderate hypertension. Multiple doses of IBI3016 will be tested against placebo, administered as subcutaneous injection.

Inclusion Criteria:

1. Signed informed consent.
2. Males or females aged 18 to 75 years.
3. Diagnosis of primary hypertension without anti-HTN medication or with one anti-HTN medication
4. Mean sitting SBP ≥140 mmHg and < 170 mmHg measured by OBPM.
5. Participants able to understand and comply with study procedures.

Exclusion Criteria:

1. Known history of secondary hypertension.

2. Orthostatic hypotension.

3. Laboratory parameter assessments outside of range at screening：

   • Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) > 2× Upper Limit of Normal (ULN)
   • Total Bilirubin > 1.5× ULN
   • International Normalized Ratio (INR) > 2.0
   • Serum Potassium > 5 mg/L
   • Estimated Glomerular Filtration Rate (eGFR) ≤ 45 mL/min/1.73m²
   • QTcF > 480 ms

4. Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.

5. Current or history of intolerance to ACEi and/or ARBs.

6. Acute myocardial infarction (AMI), unstable angina, percutaneous coronary intervention (PCI) , coronary artery bypass graft (CABG), ischemic or hemorrhagic stroke, transient ischemic attack, or clinically significant cardiac arrhythmias within 6 months prior to screening. Any history of congestive heart failure.

Other protocol-defined inclusion/exclusion criteria may apply